Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer.

Mingozzi F, Liu YL, Dobrzynski E, Kaufhold A, Liu JH, Wang Y, Arruda VR, High KA, Herzog RW.

J Clin Invest. 2003 May;111(9):1347-56.

2.

Tolerance induction by viral in vivo gene transfer.

Dobrzynski E, Herzog RW.

Clin Med Res. 2005 Nov;3(4):234-40. Review.

3.

Role of antigen-specific regulatory CD4+CD25+ T cells in tolerance induction after neonatal IP administration of AAV-hF.IX.

Shi Y, Falahati R, Zhang J, Flebbe-Rehwaldt L, Gaensler KM.

Gene Ther. 2013 Oct;20(10):987-96. doi: 10.1038/gt.2013.22. Epub 2013 Jun 13.

4.

Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX.

Fields PA, Kowalczyk DW, Arruda VR, Armstrong E, McCleland ML, Hagstrom JN, Pasi KJ, Ertl HC, Herzog RW, High KA.

Mol Ther. 2000 Mar;1(3):225-35.

5.

Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer.

Cao O, Dobrzynski E, Wang L, Nayak S, Mingle B, Terhorst C, Herzog RW.

Blood. 2007 Aug 15;110(4):1132-40. Epub 2007 Apr 16.

6.

Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer.

Cooper M, Nayak S, Hoffman BE, Terhorst C, Cao O, Herzog RW.

Hum Gene Ther. 2009 Jul;20(7):767-76. doi: 10.1089/hum.2008.161.

7.

Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cells.

Dobrzynski E, Fitzgerald JC, Cao O, Mingozzi F, Wang L, Herzog RW.

Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4592-7. Epub 2006 Mar 10.

8.

Major role of local immune responses in antibody formation to factor IX in AAV gene transfer.

Wang L, Cao O, Swalm B, Dobrzynski E, Mingozzi F, Herzog RW.

Gene Ther. 2005 Oct;12(19):1453-64.

PMID:
15889137
9.

Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy.

Herzog RW, Fields PA, Arruda VR, Brubaker JO, Armstrong E, McClintock D, Bellinger DA, Couto LB, Nichols TC, High KA.

Hum Gene Ther. 2002 Jul 20;13(11):1281-91.

PMID:
12162811
10.

Muscle as a target for supplementary factor IX gene transfer.

Hoffman BE, Dobrzynski E, Wang L, Hirao L, Mingozzi F, Cao O, Herzog RW.

Hum Gene Ther. 2007 Jul;18(7):603-13.

PMID:
17594244
11.

Persistent expression of hF.IX After tolerance induction by in utero or neonatal administration of AAV-1-F.IX in hemophilia B mice.

Sabatino DE, Mackenzie TC, Peranteau W, Edmonson S, Campagnoli C, Liu YL, Flake AW, High KA.

Mol Ther. 2007 Sep;15(9):1677-85. Epub 2007 Jun 12.

12.

Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B.

Rogers GL, Martino AT, Zolotukhin I, Ertl HC, Herzog RW.

J Transl Med. 2014 Jan 25;12:25. doi: 10.1186/1479-5876-12-25.

13.
14.

Therapeutic levels of factor IX expression using a muscle-specific promoter and adeno-associated virus serotype 1 vector.

Liu YL, Mingozzi F, Rodriguéz-Colôn SM, Joseph S, Dobrzynski E, Suzuki T, High KA, Herzog RW.

Hum Gene Ther. 2004 Aug;15(8):783-92.

PMID:
15319035
15.

Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia B.

Mingozzi F, Chen Y, Murphy SL, Edmonson SC, Tai A, Price SD, Metzger ME, Zhou S, Wright JF, Donahue RE, Dunbar CE, High KA.

Mol Ther. 2012 Jul;20(7):1410-6. doi: 10.1038/mt.2012.84. Epub 2012 May 8.

16.

Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9.

Fields PA, Arruda VR, Armstrong E, Chu K, Mingozzi F, Hagstrom JN, Herzog RW, High KA.

Mol Ther. 2001 Sep;4(3):201-10.

17.

Hepatic control elements promote long-term expression of human coagulation factor IX gene in hydrodynamically transfected mice.

Kim HS, Kim JC, Lee YK, Kim JS, Park YS.

J Gene Med. 2011 Jul;13(7-8):365-72. doi: 10.1002/jgm.1583.

PMID:
21710610
18.

Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 mice.

Fields PA, Armstrong E, Hagstrom JN, Arruda VR, Murphy ML, Farrell JP, High KA, Herzog RW.

Gene Ther. 2001 Mar;8(5):354-61.

19.

Immune response after neonatal transfer of a human factor IX-expressing retroviral vector in dogs, cats, and mice.

Xu L, Mei M, Haskins ME, Nichols TC, O'donnell P, Cullen K, Dillow A, Bellinger D, Ponder KP.

Thromb Res. 2007;120(2):269-80. Epub 2006 Nov 7.

PMID:
17095052
20.

Immune deviation by mucosal antigen administration suppresses gene-transfer-induced inhibitor formation to factor IX.

Cao O, Armstrong E, Schlachterman A, Wang L, Okita DK, Conti-Fine B, High KA, Herzog RW.

Blood. 2006 Jul 15;108(2):480-6. Epub 2006 Mar 16.

Supplemental Content

Support Center